The intra-vitreous injection (IVT) of anti-VEGF (vascular endothelial growth factor) is currently the standard treatment for retinal neovascularization. The VEGF stimulates endothelial cells' proliferation and migration. It also increases microvascular permeability. If the VEGFs have proven their efficiency in the decrease of choroidal neovascular proliferation, their impact of the head of the optic nerve's microvasculature is yet unknown. Knowing that this microvasculature provides the retinal nerve fibers with oxygen, located in the area of the head of the optic nerve, a vasoconstriction induced by the anti-VEGF may have an incidence on the loss of retinal nerve fibers.

Inclusion Criteria:

• Age ≥18 years old
• Patients treated with anti-VEGF according to the French summary of product characteristics (SPC)
• Patients who have been informed of the trial and who are not opposed to participate in the study

Exclusion Criteria:

• Patients presenting a retinal condition, including the optic nerve
• Patients treated with anti-VEGF in both eyes
• Pregnant women
• Lack of affiliation to social security or universal health coverage

Patients will be recruited during a consultation in ophtalmology after prescription of an anti-VEGF treatment.

The study will not change the patient's usual care schedule. Only a different analysis of the images obtained by SD -OCT will be performed, and a gonioscopy will be carried out systematically the inclusion of patient and 12 months.

The data for the study will be collected at the inclusion visit and at the final visit of the study at 12 months.